CN101550072B - 白茅根有效组分及其制备方法 - Google Patents
白茅根有效组分及其制备方法 Download PDFInfo
- Publication number
- CN101550072B CN101550072B CN200810052602.6A CN200810052602A CN101550072B CN 101550072 B CN101550072 B CN 101550072B CN 200810052602 A CN200810052602 A CN 200810052602A CN 101550072 B CN101550072 B CN 101550072B
- Authority
- CN
- China
- Prior art keywords
- minute
- ethanol
- rhizome
- column
- moving phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 240000007171 Imperata cylindrica Species 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 145
- 241001598107 Imperata Species 0.000 claims abstract description 89
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 54
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000003480 eluent Substances 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 244000025254 Cannabis sativa Species 0.000 claims description 53
- 238000004262 preparative liquid chromatography Methods 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 11
- 238000000926 separation method Methods 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 10
- -1 reflux 1 hour Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000011068 loading method Methods 0.000 claims description 7
- 238000004440 column chromatography Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 abstract description 18
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 74
- 239000000243 solution Substances 0.000 description 52
- 230000002401 inhibitory effect Effects 0.000 description 43
- 230000004083 survival effect Effects 0.000 description 37
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 35
- 235000019441 ethanol Nutrition 0.000 description 31
- 239000003814 drug Substances 0.000 description 24
- 235000015097 nutrients Nutrition 0.000 description 21
- 229960000583 acetic acid Drugs 0.000 description 15
- 238000004128 high performance liquid chromatography Methods 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000012362 glacial acetic acid Substances 0.000 description 10
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 239000013543 active substance Substances 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000012490 blank solution Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 239000002547 new drug Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 238000007605 air drying Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 238000001819 mass spectrum Methods 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000009514 concussion Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 2
- 229960000641 zorubicin Drugs 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000105 evaporative light scattering detection Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229960004838 phosphoric acid Drugs 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- NGSFWBMYFKHRBD-UHFFFAOYSA-N sodium;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O NGSFWBMYFKHRBD-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 229940032330 sulfuric acid Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
白茅根B01组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.09 | 0.36 | 0.06 | 0.08 |
抑制率(%) | 89.67 | 0.00 | 100.0 | 92.08 |
RSD(%) | 4.66 | 5.29 | 5.71 | 2.65 |
白茅根B02组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.10 | 0.36 | 0.06 | 0.08 |
抑制率(%) | 86.17 | 0.00 | 100.00 | 92.08 |
RSD(%) | 6.27 | 5.29 | 5.71 | 2.65 |
白茅根B05组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.07 | 0.36 | 0.06 | 0.08 |
抑制率(%) | 95.50 | 0.00 | 100.00 | 92.08 |
RSD(%) | 0.96 | 5.29 | 5.71 | 2.65 |
白茅根B06组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.08 | 0.36 | 0.06 | 0.08 |
抑制率(%) | 92.67 | 0.00 | 100.00 | 92.08 |
RSD(%) | 2.00 | 5.29 | 5.71 | 2.65 |
白茅根B07组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.09 | 0.36 | 0.06 | 0.08 |
抑制率(%) | 91.33 | 0.00 | 100.00 | 92.08 |
RSD(%) | 1.64 | 5.29 | 5.71 | 2.65 |
白茅根B08组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.09 | 0.36 | 0.06 | 0.08 |
抑制率(%) | 88.83 | 0.00 | 100.00 | 92.08 |
RSD(%) | 2.27 | 5.29 | 5.71 | 2.65 |
白茅根B09组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.10 | 0.36 | 0.06 | 0.08 |
抑制率(%) | 86.50 | 0.00 | 100.00 | 92.08 |
RSD(%) | 3.52 | 5.29 | 5.71 | 2.65 |
白茅根B10组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.09 | 0.36 | 0.06 | 0.08 |
抑制率(%) | 89.17 | 0.00 | 100.00 | 92.08 |
RSD(%) | 3.82 | 5.29 | 5.71 | 2.65 |
白茅根B11组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.10 | 0.36 | 0.06 | 0.08 |
抑制率(%) | 88.17 | 0.00 | 100.00 | 92.08 |
RSD(%) | 0.74 | 5.29 | 5.71 | 2.65 |
白茅根B12组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.08 | 0.36 | 0.06 | 0.08 |
抑制率(%) | 93.33 | 0.00 | 100.00 | 92.08 |
RSD(%) | 1.77 | 5.29 | 5.71 | 2.65 |
白茅根B13组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.07 | 0.36 | 0.06 | 0.08 |
抑制率(%) | 96.83 | 0.00 | 100.00 | 92.08 |
RSD(%) | 1.02 | 5.29 | 5.71 | 2.65 |
白茅根B14组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.09 | 0.36 | 0.06 | 0.08 |
抑制率(%) | 90.83 | 0.00 | 100.00 | 92.08 |
RSD(%) | 7.27 | 5.29 | 5.71 | 2.65 |
白茅根B15组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.11 | 0.36 | 0.06 | 0.08 |
抑制率(%) | 85.00 | 0.00 | 100.00 | 92.08 |
RSD(%) | 4.04 | 5.29 | 5.71 | 2.65 |
白茅根B01组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.25 | 0.59 | 0.16 | 0.17 |
抑制率(%) | 79.19 | 0.00 | 100.00 | 96.86 |
RSD(%) | 1.417 | 4.861 | 5.093 | 5.272 |
白茅根B02组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.26 | 0.59 | 0.16 | 0.17 |
抑制率(%) | 76.28 | 0.00 | 100.00 | 96.86 |
RSD(%) | 7.557 | 4.861 | 5.093 | 5.272 |
白茅根B05组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.28 | 0.59 | 0.16 | 0.17 |
抑制率(%) | 72.21 | 0.00 | 100.00 | 96.86 |
RSD(%) | 7.337 | 4.861 | 5.093 | 5.272 |
白茅根B06组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.25 | 0.59 | 0.16 | 0.17 |
抑制率(%) | 80.12 | 0.00 | 100.00 | 96.86 |
RSD(%) | 0.864 | 4.861 | 5.093 | 5.272 |
白茅根B07组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.24 | 0.59 | 0.16 | 0.17 |
抑制率(%) | 82.09 | 0.00 | 100.00 | 96.86 |
RSD(%) | 2.984 | 4.861 | 5.093 | 5.272 |
白茅根B08组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.27 | 0.59 | 0.16 | 0.17 |
抑制率(%) | 75.12 | 0.00 | 100.00 | 96.86 |
RSD(%) | 1.059 | 4.861 | 5.093 | 5.272 |
白茅根B09组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.25 | 0.59 | 0.16 | 0.17 |
抑制率(%) | 78.95 | 0.00 | 100.00 | 96.86 |
RSD(%) | 5.36 | 4.861 | 5.093 | 5.272 |
白茅根B10组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.22 | 0.59 | 0.16 | 0.17 |
抑制率(%) | 87.09 | 0.00 | 100.00 | 96.86 |
RSD(%) | 4.27 | 4.861 | 5.093 | 5.272 |
白茅根B11组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.19 | 0.59 | 0.16 | 0.17 |
抑制率(%) | 93.95 | 0.00 | 100.00 | 96.86 |
RSD(%) | 6.84 | 4.861 | 5.093 | 5.272 |
白茅根B12组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.22 | 0.59 | 0.16 | 0.17 |
抑制率(%) | 86.63 | 0.00 | 100.00 | 96.86 |
RSD(%) | 6.18 | 4.861 | 5.093 | 5.272 |
白茅根B13组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.15 | 0.59 | 0.16 | 0.17 |
抑制率(%) | 102.33 | 0.00 | 100.00 | 96.86 |
RSD(%) | 6.60 | 4.861 | 5.093 | 5.272 |
白茅根B14组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.18 | 0.59 | 0.16 | 0.17 |
抑制率(%) | 95.35 | 0.00 | 100.00 | 96.86 |
RSD(%) | 7.07 | 4.861 | 5.093 | 5.272 |
白茅根B15组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.16 | 0.59 | 0.16 | 0.17 |
抑制率(%) | 100.12 | 0.00 | 100.00 | 96.86 |
RSD(%) | 3.99 | 4.861 | 5.093 | 5.272 |
白茅根B01组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.12 | 0.69 | 0.04 | 0.12 |
抑制率(%) | 87.15 | 0.00 | 100.00 | 87.19 |
RSD(%) | 0.57 | 6.622 | 1.33 | 4.363 |
白茅根B02组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.13 | 0.69 | 0.04 | 0.12 |
抑制率(%) | 86.92 | 0.00 | 100.00 | 87.19 |
RSD(%) | 1.13 | 6.622 | 1.33 | 4.363 |
白茅根B05组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.12 | 0.69 | 0.04 | 0.12 |
抑制率(%) | 87.54 | 0.00 | 100.00 | 87.19 |
RSD(%) | 2.34 | 6.622 | 1.33 | 4.363 |
白茅根B07组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.12 | 0.69 | 0.04 | 0.12 |
抑制率(%) | 87.46 | 0.00 | 100.00 | 87.19 |
RSD(%) | 4.07 | 6.622 | 1.33 | 4.363 |
白茅根B08组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.13 | 0.69 | 0.04 | 0.12 |
抑制率(%) | 86.85 | 0.00 | 100.00 | 87.19 |
RSD(%) | 2.82 | 6.622 | 1.33 | 4.363 |
白茅根B09组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.12 | 0.69 | 0.04 | 0.12 |
抑制率(%) | 87.62 | 0.00 | 100.00 | 87.19 |
RSD(%) | 7.63 | 6.622 | 1.33 | 4.363 |
白茅根B10组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.12 | 0.69 | 0.04 | 0.12 |
抑制率(%) | 87.92 | 0.00 | 100.00 | 87.19 |
RSD(%) | 5.37 | 6.622 | 1.33 | 4.363 |
白茅根B12组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.11 | 0.69 | 0.04 | 0.12 |
抑制率(%) | 89.00 | 0.00 | 100.00 | 87.19 |
RSD(%) | 1.90 | 6.622 | 1.33 | 4.363 |
白茅根B13组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.11 | 0.69 | 0.04 | 0.12 |
抑制率(%) | 88.62 | 0.00 | 100.00 | 87.19 |
RSD(%) | 2.48 | 6.622 | 1.33 | 4.363 |
白茅根B14组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.13 | 0.69 | 0.04 | 0.12 |
抑制率(%) | 86.62 | 0.00 | 100.0 | 87.19 |
RSD(%) | 5.57 | 6.622 | 1.33 | 4.363 |
白茅根B15组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.11 | 0.73 | 0.06 | 0.12 |
抑制率(%) | 92.46 | 0.00 | 100.00 | 91.68 |
RSD(%) | 5.76 | 2.26 | 4.53 | 4.426 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810052602.6A CN101550072B (zh) | 2008-04-02 | 2008-04-02 | 白茅根有效组分及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810052602.6A CN101550072B (zh) | 2008-04-02 | 2008-04-02 | 白茅根有效组分及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101550072A CN101550072A (zh) | 2009-10-07 |
CN101550072B true CN101550072B (zh) | 2014-03-19 |
Family
ID=41154599
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810052602.6A Expired - Fee Related CN101550072B (zh) | 2008-04-02 | 2008-04-02 | 白茅根有效组分及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101550072B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103463493B (zh) * | 2013-09-20 | 2015-04-08 | 浙江大学 | 一种用于治疗肾炎性血尿的中药颗粒剂 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1903239A (zh) * | 2005-07-29 | 2007-01-31 | 天津天士力现代中药研究开发有限公司 | 一种川芎药材的提取分离方法 |
-
2008
- 2008-04-02 CN CN200810052602.6A patent/CN101550072B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1903239A (zh) * | 2005-07-29 | 2007-01-31 | 天津天士力现代中药研究开发有限公司 | 一种川芎药材的提取分离方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101550072A (zh) | 2009-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101433563B (zh) | 诃子有效组分及其制备方法与用途 | |
CN101549001B (zh) | 艾叶有效组分及其制备方法 | |
CN101550081B (zh) | 一种侧柏叶的有效组分及其制备方法 | |
CN101550120B (zh) | 一种艾叶的有效组分及其制备方法 | |
CN101428043B (zh) | 诃子有效组分及其制备方法与用途 | |
CN101507737B (zh) | 一种五倍子的有效组分及其制备方法与用途 | |
CN101347518A (zh) | 一种赤芍的有效组分及其制备方法与用途 | |
CN101550072B (zh) | 白茅根有效组分及其制备方法 | |
CN101549000B (zh) | 白薇有效组分及其制备方法 | |
CN101549111B (zh) | 一种白茅根有效组分及其制备方法 | |
CN101347534B (zh) | 茜草有效组分及其制备方法 | |
CN101347533B (zh) | 一种茜草的有效组分及其制备方法与用途 | |
CN101433560B (zh) | 五倍子有效组分及其制备方法与用途 | |
CN101433571B (zh) | 王不留行有效组分及其制备方法与用途 | |
CN101347508B (zh) | 防己有效组分及其制备方法 | |
CN101433558B (zh) | 五倍子的有效组分及其制备方法与用途 | |
CN101549048B (zh) | 一种马鞭草的有效组分及其制备方法 | |
CN101347473A (zh) | 一种穿心莲的有效组分及其制备方法与用途 | |
CN101549036B (zh) | 巴戟天有效组分及其制备方法 | |
CN101428053B (zh) | 王不留行有效组分及其制备方法与用途 | |
CN101347474B (zh) | 一种当归的有效组分及其制备方法与用途 | |
CN101433692B (zh) | 一种姜黄的有效组分及其制备方法与用途 | |
CN101433693B (zh) | 一种姜黄的有效组分及其制备方法 | |
CN101433570B (zh) | 王不留行有效组分及其制备方法与用途 | |
CN101428129B (zh) | 一种姜黄的有效组分及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Applicant after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Applicant before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: TIANJIN TIANSHILI PHARMACEUTICAL CO., LTD. TO: TASLY PHARMACEUTICAL GROUP CO., LTD. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140319 Termination date: 20210402 |
|
CF01 | Termination of patent right due to non-payment of annual fee |